Skip to main content
. 2022 May 20;3(1):sgac032. doi: 10.1093/schizbullopen/sgac032

Table 1.

Demographics of the Patient and Control Subjects Used for Developing the Classifier. Demographics of Others Used for Validating the Classifier (Test-1 and Test-2) Can be Found in Supplementary Table 1

Schizophrenia (SCZ) Bipolar Affective Disorder (BPAD) Major Depression Disorder (MDD) Healthy Control (CON)
Training data (Train; N = 539)
N 120 141 136 142
Sex, 35:85 81:60 86:50:00 84:58:00
Female:Male
Age (years), 43.0 47.0 46.5 28.0
Median (Q1, Q3) (32.8, 51.2) (38.0, 55.0) (36.0, 57.0) (23.0, 45.0)
Education (years), 12.0 15.0 13.5 15.0
Median (Q1, Q3) (9.5, 15.0) (12.0, 15.0) (10.0, 15.0) (13.5, 16.0)
Illness age of onset (years), 22.0 27.0 30.0
Median (Q1, Q3) (19.0, 28.0) (21.0, 35.0) (23.0, 41.0)
Illness duration (years), 19.0 17.0 11.0
Median (Q1, Q3) (13.8, 27.5) (9.0, 26.0) (6.0, 21.0)
CPZ, 525.0 50.0 0.0
Median (Q1, Q3) (237.5, 862.5) (0.0, 150.0) (0.0, 33.2)
Nicotine (cigarettes/day), 5.0 0.0 0.0 0.0
Median (Q1, Q3) (0.0, 20.0) (0.0, 10.0) (0.0, 0.0) (0.0, 0.0)
Caffeine intake (cups/day), 4.0 4.0 4.0 3.0
Median (Q1, Q3) (2.2, 7.0) (2.0, 5.0) (3.0, 6.0) (1.0, 5.0)
HADS Anxiety, 8.0 8.0 11.0 4.0
Median (Q1, Q3) (6.0, 12.0) (4.0, 12.0) (7.0, 14.0) (2.0, 6.0)
HADS Depression, 7.0 5.0 8.0 1.0
Median (Q1, Q3) (4.0, 9.0) (2.0, 10.0) (5.0, 12.0) (0.0, 3.0)

Note: CPZ, Chlorpromazine equivalents (mg/day). Q1, Q3 are first and third quartiles. Education indicates years in full time education.